Search results
Results from the WOW.Com Content Network
Its Genentech Ophthalmology Co-pay Program helps make treatments more accessible to patients. Novartis AG is another key player, known for its focus on ophthalmology, particularly with drugs like Lucentis and Beovu (brolucizumab) for wet AMD. The company is also expanding its research into diabetic retinopathy through phase 3 trials for Beovu.
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009.
Lineage is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. The company changed its name from BioTime Inc. to Lineage Cell Therapeutics less than one year following its appointment of a new CEO, Brian Culley, in August 2018 and completing a series of corporate transactions including the distribution of AgeX Therapeutics, the acquisition of ...
From 2017 to 2018, he was the CEO of Genentech. [6] While at Genentech, he developed its immunology and ophthalmology divisions, managed the sales of Rituxan, Raptiva, and Xolair, and directed Roche's late-stage portfolio committee for nearly four years, where he was responsible for determining late-stage clinical trial advancements. [6]
Genentech will also have the option to select additional targets in return for an option exercise fee. Price Action: PIRS shares are up 49.3% at $2.76 on the last check Tuesday.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
The article Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO originally appeared on Fool.com. Try any of our Foolish newsletter services free for 30 days .
Genentech previously said the use of the drug in the indication accounts for a fraction of its overall revenue. The U.S. Food and Drug Administration had granted accelerated approval to Gavreto in ...